Teachers:
PD Dr. Marta Fadda, Lecturer of Bioethics, Faculty of Biomedical Sciences, Università della Svizzera
italiana, Lugano
Dr. Pietro Gervasoni, Managing Director of Swissethics, Bern
Prof. Silvio Garattini, President and Founder of Mario Negri Institute, Milan
Tamara Kohler, Swiss Clinical Trial Organization
Dr. Valter Torri, Head of Laboratory, Mario Negri Institute, Milan
Dr. Rita Banzi, Center for Health Regulatory Policies, Mario Negri Institute, Milan
Objectives:
The increasing knowledge in molecular biology and the development of the techniques for the evaluation of
the biological processes and of their interaction have brought about, in preclinical and clinical research, what
is called precision medicine, to select the treatment that works best for an individual.
The development of new therapeutic approaches raises many ethical issues, of which investigators’ also and
in particular at the preclinical level, should be aware of and take into consideration in their decisions and
activities.
The objectives of this course are to increase this awareness of the ethical issues and of their potential impact
in the selection and preclinical evaluation of new molecules, in the decision making process, in the care of
patients and in the social environment.
In particular,
in the active involvement of patients already at the beginning of the clinical project;
- in the planning and modalities of activation of clinical studies;
- in the selection of treatment, relationship and care of patients;
- in the collection of data and biological tissues;
- in the analysis, report, publication and sharing of data and results;
- in the registration, selling and marketing of therapeutic compounds in Europe;
- in the new aspects of biomedical research involving tissue cultures and human embryos.